Supported by the positive outcomes of combinational therapies involving MDM2 inhibitors, therapies targeting E3s upstream of PTEN may offer synergistic benefits in overcoming drug resistance and improving treatment outcomes in cancers with reduced PTEN expression. This evidence concerns the gene MDM2 and cancer.